Ken Griffin Mainz Biomed N.V. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mainz Biomed N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,157 shares of MYNZ stock, worth $6,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,157
Previous 33,244
45.38%
Holding current value
$6,899
Previous $38,000
52.63%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MYNZ
# of Institutions
13Shares Held
147KCall Options Held
0Put Options Held
0-
Northern Trust Corp Chicago, IL29.9KShares$11,3740.0% of portfolio
-
Xtx Topco LTD London, X028.8KShares$10,9340.0% of portfolio
-
Vontobel Holding Ltd.25KShares$9,5000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA15.2KShares$5,7710.0% of portfolio
-
Greenwich Investment Management, Inc. Stamford, CT12KShares$4,5530.01% of portfolio
About MAINZ BIOMED N.V.
- Ticker MYNZ
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 14,483,000
- Market Cap $5.5M
- Description
- Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments...